Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use COLUMVI® safely and effectively. See full prescribing information for COLUMVI. COLUMVI (glofitamab-gxbm) injection, for intravenous use Initial U.S. Approval: 2023
Medication labelWhy this: Advisory · dailymed-prescription
COLUMVI is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.1)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
- generic_name
- glofitamab
- product_names
- Glofitamab
- ndc
- 50242-125, 50242-127, 50242-127-01, 50242-125-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en